Clinical Pharmacology of Antifungal Compounds

Infect Dis Clin North Am. 2003 Mar;17(1):159-91, ix. doi: 10.1016/s0891-5520(02)00068-5.

Abstract

Prompted by the worldwide surge in fungal infections, the past decade has witnessed a considerable expansion in antifungal drug research. New compounds have entered the clinical arena, and major progress has been made in defining paradigms of antifungal therapies. This article provides an up-to-date review on the clinical pharmacology, indications, and dosage recommendations of approved and currently investigational therapeutics for treatment of invasive fungal infections in adult and pediatric patients.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / classification
  • Anti-Bacterial Agents / metabolism
  • Anti-Bacterial Agents / pharmacokinetics
  • Antifungal Agents / metabolism
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use*
  • Drug Design
  • Echinocandins
  • Flucytosine / metabolism
  • Flucytosine / pharmacology
  • Fungal Proteins*
  • Humans
  • Immunocompromised Host
  • Molecular Structure
  • Mycoses / drug therapy*
  • Mycoses / prevention & control
  • Peptides*
  • Peptides, Cyclic*
  • Polyenes / classification
  • Polyenes / pharmacokinetics
  • Triazoles / classification
  • Triazoles / pharmacokinetics

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Echinocandins
  • Fungal Proteins
  • Peptides
  • Peptides, Cyclic
  • Polyenes
  • Triazoles
  • echinocandin B
  • Flucytosine